%0 Journal Article
%T EGFR突变的非小细胞肺癌脑转移患者的靶向药物选择<br>Targeted Drug Selection in Non-Small Cell Lung Cancer Patients with EGFR Mutation-Induced Brain Metastases
%A 杨宗辉
%A 山凤连
%J Journal of Clinical Personalized Medicine
%P 319-330
%@ 2334-3443
%D 2025
%I Hans Publishing
%R 10.12677/jcpm.2025.42180
%X 肺癌是全球死亡率最高的癌症之一&#65292;其中非小细胞肺癌约占原发性肺癌的80%左右&#65292;而其中40%有脑部的损伤。非小细胞肺癌的突变位点中EGFR和ALK突变为发生脑转移的主要突变类型&#65292;而发生脑转移患者多伴有预后不良&#65292;当前肺癌的主要治疗手段包括手术、化疗、放疗和免疫治疗&#65292;但这些治疗手段对于脑转移患者临床疗效都不显著&#65292;而国际上的研究显示靶向药物对于中枢神经系统具有良好的渗透率&#65292;对于肺癌脑转移患者可能会有奇效。本文通过对国际上针对EGFR突变的酪氨酸激酶抑制剂的非小细胞肺癌脑转移患者的疗效进行总结对比&#65292;以期为EGFR突变的非小细胞肺癌脑转移患者的治疗提供参考。<br>Lung cancer is among the cancers with the highest mortality rates globally. Non-small cell lung cancer (NSCLC) accounts for approximately 80% of primary lung cancers, with 40% of these cases presenting with brain metastases. Among the mutation sites in NSCLC, EGFR and ALK mutations are the predominant types associated with brain metastasis, and patients with such metastases often experience a poor prognosis. Currently, the main treatment modalities for lung cancer include surgery, chemotherapy, radiotherapy, and immunotherapy. However, these treatments are often ineffective for patients with brain metastases. International studies have indicated that targeted therapies exhibit good penetration into the central nervous system and may offer significant benefits for patients with lung cancer and brain metastases. This article aims to summarize the efficacy of international tyrosine kinase inhibitors targeting EGFR mutations in patients with NSCLC and brain metastases. The comparison is anticipated to provide valuable insights for the treatment of patients with EGFR-mutated NSCLC and brain metastases.
%K 非小细胞肺癌&#65292
%K EGFR突变&#65292
%K 脑转移&#65292
%K 靶向治疗&#65292
%K 酪氨酸激酶抑制剂<br>Non-Small Cell Lung Cancer
%K EGFR Mutation
%K Brain Metastasis
%K Targeted Therapy
%K Tyrosine Kinase Inhibitor
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=110601